aTyr Pharma, Inc.
ATYR
Positions held
Your positionsATYR isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $25.04M | Enterprise value | -$21.27M | Trailing P/E | — | Forward P/E | -0.54 |
| PEG | — | Price / book | 0.51 | Beta | 0.91 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | -336.1% |
| Profit margin | 0.0% | ROE | -98.7% | ROA | -46.6% | Debt / equity | 0.23 |
| Current ratio | 5.12 | Free cash flow | -$31.71M | Analyst recommendation | buy | Mean target | $2.86 |
| 52w high | $1.12 | 52w low | $0.25 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.2M | $0.0M |
| Op margin | — | — | — | -14076.3% | — |
| Net income | -$10.3M | -$10.8M | -$14.0M | -$25.7M | -$19.5M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$10.9M | -$11.4M | -$14.8M | -$26.7M | -$20.3M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.2M | $0.2M | $0.4M | $10.4M |
| Op margin | -40856.3% | -28899.6% | -15557.8% | -446.8% |
| Net income | -$74.1M | -$64.0M | -$50.4M | -$45.3M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$77.6M | -$67.9M | -$54.9M | -$46.4M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-24 · Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
2026-09-24 · aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis
2026-09-24 · BC-Most Active Stocks
2026-09-24 · Top Premarket Gainers
2026-09-24 · aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
2026-09-01 · aTyr Pharma Updates Timing of FDA Response for Planned Phase 3 Trial of Efzofitimod
2026-08-07 · Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans
2026-08-07 · Atyr Pharma: Q2 Earnings Snapshot
2026-08-07 · ATyr Pharma Fiscal Q2 Loss Narrows
Price (daily)
Full chart · RSI · MACD · patterns